BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 26680454)

  • 21. Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.
    Weinberger P; Ponny SR; Xu H; Bai S; Smallridge R; Copland J; Sharma A
    Thyroid; 2017 Feb; 27(2):236-252. PubMed ID: 27796151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.
    Khan SA; Ci B; Xie Y; Gerber DE; Beg MS; Sherman SI; Cabanillas ME; Busaidy NL; Burtness BA; Heilmann AM; Bailey M; Ross JS; Sher DJ; Ali SM
    Head Neck; 2019 Jun; 41(6):1928-1934. PubMed ID: 30758123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma.
    Stosic A; Fuligni F; Anderson ND; Davidson S; de Borja R; Acker M; Forte V; Campisi P; Propst EJ; Wolter NE; Chami R; Mete O; Malkin D; Shlien A; Wasserman JD
    Cancer Res; 2021 Nov; 81(22):5625-5637. PubMed ID: 34535459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
    Smith N; Nucera C
    J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.
    Faustino A; Couto JP; Pópulo H; Rocha AS; Pardal F; Cameselle-Teijeiro JM; Lopes JM; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1139-49. PubMed ID: 22549934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
    Kunstman JW; Juhlin CC; Goh G; Brown TC; Stenman A; Healy JM; Rubinstein JC; Choi M; Kiss N; Nelson-Williams C; Mane S; Rimm DL; Prasad ML; Höög A; Zedenius J; Larsson C; Korah R; Lifton RP; Carling T
    Hum Mol Genet; 2015 Apr; 24(8):2318-29. PubMed ID: 25576899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
    Barollo S; Pezzani R; Cristiani A; Redaelli M; Zambonin L; Rubin B; Bertazza L; Zane M; Mucignat-Caretta C; Bulfone A; Pennelli G; Casal Ide E; Pelizzo MR; Mantero F; Moro S; Mian C
    Thyroid; 2014 May; 24(5):809-19. PubMed ID: 24295088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
    Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
    BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
    Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
    Lee JJ; Wang TY; Liu CL; Chien MN; Chen MJ; Hsu YC; Leung CH; Cheng SP
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2930-2940. PubMed ID: 28575350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
    Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
    Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.
    Ganly I; Ricarte Filho J; Eng S; Ghossein R; Morris LG; Liang Y; Socci N; Kannan K; Mo Q; Fagin JA; Chan TA
    J Clin Endocrinol Metab; 2013 May; 98(5):E962-72. PubMed ID: 23543667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation.
    Castro L; Alves S; Chaves SR; Costa JL; Soares P; Preto A
    Mol Cell Endocrinol; 2015 Nov; 415():64-75. PubMed ID: 26265449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].
    Lopes JP; Fonseca E
    Acta Med Port; 2011 Dec; 24 Suppl 4():855-68. PubMed ID: 22863493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of BRAF mutational status on expression profiles in conventional papillary thyroid carcinomas.
    Schulten HJ; Alotibi R; Al-Ahmadi A; Ata M; Karim S; Huwait E; Gari M; Al-Ghamdi K; Al-Mashat F; Al-Hamour O; Al-Qahtani MH; Al-Maghrabi J
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S6. PubMed ID: 25922907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.